Novartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer

Novartis announced the appointment of Dr Klaus Moosmayer as Chief Ethics, Risk and Compliance Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and  become a member of the Executive Committee of Novartis (ECN). Dr. Moosmayer will join Novartis on December 1, 2018 and will be based in Basel, Switzerland. He succeeds Shannon Thyme Klinger who was recently appointed Group General Counsel.

Dr. Moosmayer has been the Chief Compliance Officer of Siemens since January 1, 2014. Prior to that he served as the Chief Counsel Compliance at Siemens for four years. During this time he played a key role in building up Siemens' new, globally recognized compliance system. Prior to joining Siemens Dr Moosmayer practiced Law in Germany, specializing in white collar crime, Litigation and Business Law. He holds a Doctor of Jurisprudence (J.D) degree from Freiburg University.

Dr. Moosmayer is a recognized global leader in Ethics and Compliance. Since 2013, he has been Chair of the Anti-Corruption Taskforce of the Business and Industry Advisory Committee at the Organization for Economic Co-operation and Development (OECD). Additionally, Dr. Moosmayer is the Vice Chair of Business Compliance for the current G20 presidency and also served as Chair of Business Compliance during the 2016/17 G20 presidency.

Dr. Narasimhan said: "As we aspire to reimagine medicine, we must hold ourselves to highest ethical standards and always aim to win and maintain the trust of society and our many stakeholders. Klaus has extensive experience in leading Compliance for large global organisations and is internationally recognized in his field. As part of my executive leadership team, I am very confident that he will play a significant role in helping us to further define and shape our approach to ethics, risk and compliance in the coming years."

Dr. Moosmayer said: "It is a great honor for me to be given the opportunity to join Novartis. Society has high expectations of the Pharmaceutical industry and rightfully so. I am pleased to see that there is already a strong focus on driving personal accountability for behaviors, and generating learnings that can be applied across the organization within Novartis.  I look forward to building on this strong foundation to create a truly worldclass risk and compliance function."

The role of Chief Ethics and Compliance Officer, reporting to the CEO, was created in 2014, this step elevated the Compliance function to the highest levels in the company. On April 1, 2018, the role was further expanded to include oversight of all risk management functions and became a member of the Executive Committee of Novartis.